Searchable abstracts of presentations at key conferences in endocrinology

ea0063ep22 | Adrenal and Neuroendocrine Tumours | ECE2019

The rare outcome of pituitary adenoma treatment

Mikadze Ketevan , Bostoganashvili Nestan , Kvanchakhadze Rusudan

Abstract: A 41-year-old woman admitted Ginekological Clinic to surgical intervention due to ovarial enlargement. It was suspected diagnoses of Acromegalia according to the clinical manifestations: amenorrhea, headache, dizziness, enlarged phalangeal digits. nose. The patient underwent laboratory and instrumental investigations. MRI showed the pituitary adenoma (1.4×1.0×1.0 cm), GH, Prolactin and TSH were sharply increased, Ultrasound revealed remarkably enlarged ovar...

ea0049ep658 | Obesity | ECE2017

The role of pioglitazone and vitamin E for the treatment of NASH with or without metabolic syndrome

Khabeishvili Nino , Barbakadze Gocha , Mikadze Ketevan , Burnadze Koba

Introduction: Obesity is a global public health problem and is associated with metabolic syndrome and dyslipidemia as well as very often with non-alcoholic steatohepatitis (NASH).Aim & methods: The aim of the present study was to evaluate the preventive and curable role of vitamin E and pioglitazone (thiazolidinedione-type) in NASH patients with or without metabolic syndrome. 51 patients with NASH were divided into two groups: 26 patients with insuli...

ea0073aep305 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Comparing impact of SGLT2 inhibitors and GLP-1 agonists on lipid profile among the patients with diabetes mellitus Type 2. Results of a prospective 18-week observational study

Bostoganashvili Nestan , Kvanchakhadze Rusudan , Mikadze Ketevan , Panchulidze Manoni

BackgroundIn Georgia, significantly huge number of patients with Diabetes Mellitus Type 2 (DMT2) suffer from cardiovascular diseases (CVD) and obesity. Since, dyslipidemia is one of major factors, leading to cardiovascular (CV) mortality, it is crucial to investigate the effects of relatively novel hypoglycemic agents- Sodium Glucose Cotransporter 2 (SGLT2) inhibitors (Dapagliflozin) or Glucagon like peptide 1 (GLP-1) agonists (Liraglutide) on lipid prof...